PharmacyCodes



Simulect (Novartis Pharmaceuticals) en es it fr

Simulect (Novartis Pharmaceuticals) Brand names, Simulect (Novartis Pharmaceuticals) Analogs

Simulect (Novartis Pharmaceuticals) Brand Names Mixture

  • No information avaliable

Simulect (Novartis Pharmaceuticals) Chemical_Formula

C6378H9844N1698O1997S48

Simulect (Novartis Pharmaceuticals) RX_link

http://www.rxlist.com/cgi/generic2/basiliximab.htm

Simulect (Novartis Pharmaceuticals) fda sheet

Simulect (Novartis Pharmaceuticals) msds (material safety sheet)

Simulect (Novartis Pharmaceuticals) Synthesis Reference

No information avaliable

Simulect (Novartis Pharmaceuticals) Molecular Weight

143801.3

Simulect (Novartis Pharmaceuticals) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Simulect (Novartis Pharmaceuticals) H2O Solubility

No information avaliable

Simulect (Novartis Pharmaceuticals) State

Liquid

Simulect (Novartis Pharmaceuticals) LogP

-0.473

Simulect (Novartis Pharmaceuticals) Dosage Forms

Powder for solution

Simulect (Novartis Pharmaceuticals) Indication

For prophylactic treatment of kidney transplant rejection

Simulect (Novartis Pharmaceuticals) Pharmacology

Simulect functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Simulect (Novartis Pharmaceuticals) Absorption

No information avaliable

Simulect (Novartis Pharmaceuticals) side effects and Toxicity

No information avaliable

Simulect (Novartis Pharmaceuticals) Patient Information

No information avaliable

Simulect (Novartis Pharmaceuticals) Organisms Affected

Humans and other mammals